Table 2 Summary of TRAE (≥15%) after HE072 treatment
50 mg/m2 (n = 12) | 70 mg/m2 (n = 107) | Total (n = 119) | |
|---|---|---|---|
TEAE | 11 (91.7) | 104 (97.2) | 115 (96.6) |
Serious TEAEs | 2 (16.7) | 25 (23.4) | 27 (22.7) |
Serious TRAEs | 2 (16.7) | 20 (18.7) | 22 (18.5) |
TRAEs | 11 (91.7) | 103 (96.3) | 114 (95.8) |
Hematological | |||
Leukopenia | 7 (58.3) | 64 (59.8) | 71 (59.7) |
Anemia | 8 (66.7) | 59 (55.1) | 67 (56.3) |
Neutropenia | 6 (50.0) | 57 (53.3) | 63 (52.9) |
Lymphocytopenia | 3 (25.0) | 27 (25.2) | 30 (25.2) |
Thrombocytopenia | 2 (16.7) | 18 (16.8) | 20 (16.8) |
Non-hematological | |||
Diarrhea | 3 (25.0) | 72 (67.3) | 75 (63.0) |
Nausea | 6 (50.0) | 61 (57.0) | 67 (56.3) |
Vomiting | 4 (33.3) | 54 (50.5) | 58 (48.7) |
Fatigue | 5 (41.7) | 35 (32.7) | 40 (33.6) |
Weight loss | 2 (16.7) | 30 (28.0) | 32 (26.9) |
Decreased appetite | 1 (8.3) | 25 (23.4) | 26 (21.8) |
Abdominal pain | 0 | 22 (20.6) | 22 (18.5) |
Abnormality in laboratory examination | |||
Hypokalemia | 3 (25.0) | 37 (34.6) | 40 (33.6) |
γ-GGT elevation | 6 (50.0) | 26 (24.3) | 32 (26.9) |
Increased ALT | 5 (41.7) | 22 (20.6) | 27 (22.7) |
Hyponatremia | 3 (25.0) | 23 (21.5) | 26 (21.8) |
Increased AST | 5 (41.7) | 19 (17.8) | 24 (20.2) |
Hypoproteinemia | 2 (16.7) | 20 (18.7) | 22 (18.5) |
Hyperuricemia | 1 (8.3) | 20 (18.7) | 21 (17.6) |
Hypocalcemia | 3 (25.0) | 17 (15.9) | 20 (16.8) |
Albuminuria | 1 (8.3) | 19 (17.8) | 20 (16.8) |
Increased ALP | 2 (16.7) | 16 (15.0) | 18 (15.1) |
